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ABSTRACT
Objective: To assess the frequency of β-lactamase production and antimicrobial resistance in
Moraxella catarrhalis isolated from clinical specimens in Pakistan.
Methods: This cross sectional study (January to December 2010) was conducted in clinical
microbiology laboratory of Aga Khan University Hospital. A total of 97 clinical respiratory
specimens growing Moraxella catarrhalis were included. Frequency of β-lactamase production
and antimicrobial resistance rates against ampicillin, erythromycin, ciprofloxacin and tetracycline
were noted by performing minimum inhibitory concentration (MIC). MICs were calculated as MIC50
and MIC90.
Results: β-Lactamase production was detected in 84% of isolates, which correlated well with
high MIC of ampicillin. Majority of isolates were susceptible to erythromycin (97%) and tetracycline
(96%) with MIC90=0.12 mg/L and MIC90=1 mg/L respectively. All isolates were found susceptible to
ciprofloxacin (MIC90=0.06 mg/L).
Conclusions: Result suggests that empirical use of ampicillin should be discouraged while
treating respiratory tract infections. This also emphasizes the importance of continuous
surveillance in order to detect emerging resistance in Moraxella isolates.

1. Introduction
Over the last few decades the increasing pathogenicity
and capacity to produce β-lactamase enzyme has evolved
Moraxella catarrhalis (M. catarrhalis) from a benign
commensal to a genuine pathogen [1,2]. C urrently, it is
considered as one of the common cause of upper and
lower respiratory tract infections. Though rarely reported,
it can also cause severe infections including pneumonia,
endocarditis, septicaemia and meningitis etc[1-4]. M.
catarrhalis also contributes in mixed respiratory tract
infections with other pathogens such as Streptococcus
pneumoniae ( S. pneumoniae ) and/or Haemophilus
influenzae (H. influenzae). In such cases, β-lactamase
produced by this organism may render ampicillin
ineffective against susceptible S. pneumoniae and H.
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influenzae[5].
Sweden was the first country to report the presence
of β-lactamase in M. catarrhalis in 1977[6]. Since then
β-lactamase production has been reported from various
countries with increasing frequency (even above 90%)[7-9].
Though it remains rare, reports of increasing resistance to
other oral antibiotics useful to treat community acquired
respiratory tract infections (CARTI) are also documented in
M. catarrhalis[10,11].
I nformation regarding frequency of β -lactamase
production in M. catarrhalis is limited from Pakistan.
A study from P akistan reported 93 . 5 % ampicillin
susceptibility in M. catarrhalis but authors did not report
β-lactamase activity in those isolates[12]. Another study
reported 68.7% β-lactamase production in M. catarrhalis.
However this study had the limitations of small sample
size and use of less sensitive filter paper acidometric
test for β-lactamase detection[13]. The local antimicrobial
susceptibility data of other oral antibiotics used for
CARTI against M. catarrhalis is also missing. Surveillance
to monitor shifting trends in resistance is vital as it
ultimately influences the selection of antimicrobial agents
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available for use against a particular organism. Therefore,
this study aimed to assess the frequency of β-lactamase
production in M. catarrhalis and also drug resistance
against ampicillin, erythromycin, ciprofloxacin and
tetracycline, so as to guide empirical therapy in CARTI.
2. Material and methods
This cross sectional study was conducted from January
to D ecember 2010 in the clinical microbiology
laboratory of Aga Khan University Hospital (AKUH). The
2010

laboratory has an extensive network of more than
collection units throughout Pakistan. Through this it
caters a vast outpatient population across the country.

AKUH

200

2.1. Respiratory specimens
C linical respiratory specimens ( sputum, tracheal
aspirate, bronchoalveolar lavage, middle ear fluid,
nasopharyngeal swab/aspirate and sinus aspirate ) from
community that were received in AKUH laboratory for
culture and sensitivities during study period were
included.

2.2. Isolation of M. catarrhalis
The identification of the M. catarrhalis was confirmed
by colony morphology, G ram stain appearance and

conventional biochemical tests such as positive oxidase,
catalase, and DNAase test. Clinical isolates were saved in
glycerol-phosphate buffer at -80 °C. Duplicate samples
from same patient were excluded. D emographic data
including gender and age and seasonal distribution were
also noted.
2.3. Antimicrobial susceptibility testing
Ampicillin, erythromycin, ciprofloxacin, and tetracycline
powder were obtained from Sigma-Aldrich, UK. Minimum

inhibitory concentrations ( MIC s ) of the antimicrobials
were performed according to agar dilution method
recommended by British Society for Chemotherapy (BSAC)
[14]. Agar plates were prepared with the antimicrobials to
be tested incorporated in the media supplemented with
5% defibrinated blood in double dilution series. Bacterial
suspension 10 4 CFU /spot was prepared and applied
by the multipoint inoculator. F or testing ampicillin,
inoculum of 10 6 CFU was used. P lates were incubated
at 37 °C aerobically for 18 h. MIC breakpoints provided
by the BSAC[15] were used for interpretation and isolates
were categorized as being sensitive (S), intermediately
susceptible (I), or resistant (R).

Interpretation of the MIC breakpoints was as follows:
Ampicillin: S≤1 mg/L, R>1 mg/L; Ciprofloxacin: S≤0.5 mg/
L, R>0.5 mg/L; Tetracycline: S≤1 mg/L, I=2 mg/L, R≥2 mg/
L; Erythromycin: S≤0.25 mg/L, I=0.5 mg/L, R≥0.5 mg/L.
β - L actamase production was detected by nitrocefin
( O xoid ) test. T he reference strains used for quality

control included S. pneumoniae ATCC strain 49619 and
Staphylococcus aureus ATCC strain 29213 . MIC s were
calculated as MIC50 and MIC90 (MIC causing inhibition of 50%
and 90% of isolates, respectively).
2.4. Data management and statistical analysis

D ata was entered and analysed by the statistical
software SPSS version 19.0. Frequencies with percentages
for age and seasonal distribution, β-lactamase production
and resistance for each drug were computed.

2.5. Ethical approval
T his study was approved by the E thics R eview
Committee of the Aga Khan University, Pakistan.

3. Results
A total of 4 440 respiratory specimens were received
during study period. Out of these, 30% (1 333) were reported
positive for respiratory pathogens. A bout 60 % ( 2 680 )
specimens were received from male patients.
A total of 97/1 333 clinical respiratory specimens yielded
growth of M. catarrhalis. Amongst studied isolates of M.
catarrhalis, 71% (69) were from male and 65% (63) were
recovered from patients aged greater than 65 years. The
age distribution is shown in Table 1.
Table1
Distribution of M. catarrhalis isolates (n=97) among different age
groups.
Age range in years
0-15

16-30
31-45
46-65

>65

Number (%)
11 (11.5)
11 (11.5)
12 (12.0)
24 (25.0)
39 (40.0)

Majority of isolates (50.5%, 49) were grown in the winter
months (November-February) with the peak incidence in
the month of January (Figure 1). β-Lactamase production
was detected in 84.5% (81) of isolates, which correlated well
with the high ampicillin MIC among them. Ninety-seven
percent of isolates were found susceptible to erythromycin
with MIC90 of 0.12 mg/L and ninety-six percent susceptible
to tetracycline with MIC 90 of 1 mg/ L . A ll isolates were
susceptible to ciprofloxacin. The MIC distribution for the
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four antibiotics tested is given in Table 2.
Table 2
Distribution of MICs (µg/mL)) for antimicrobials tested against M.
catarrhalis isolates (n=97).
Ampicillin Ciprofloxacin Tetracycline Erythromycin

MIC

-

9

-

0.25

-

2

0.06

-

11

128
64

2

32

3

16

4

8

17

2

34

4

21

1

0.5

4

0.125
0.015

MIC90
MIC50
MIC range
Sensitive (%)

1

10

2

13

1

8

5

40

1

0.125

0.06-8

0.03-1

44

8

0.06

0.125-64

0.015-0.5

41

-

32
0.03

15.5

57

2

5

2

1

-

1

3

3

0.03

-

12

-

0.5

100

0.06

96

97

BSAC break points of MIC s for ampicillin ( mg/ L ) : S ≤ 1 , R > 1 ,
ciprofloxacin (mg/L): S≤0.5, R>0.5, tetracycline (mg/L): S≤1, I=2,
R≥2 and erythromycin (mg/L): S≤0.25, I=0.5, R≥0.5.
25

23

Frequency of isolates

20

15

15

10

10

11

7
5

7
4

5

4

5

5

4

0

January February March April May June July August September October November December

Figure 1. Monthly rate of isolation of M. catarrhalis.

4. Discussion
This study suggests that empirical use of ampicillin/
amoxicillin in CARTI would miss β-lactamase producing
M. catarrhalis strains and may lead to treatment failure.
It may also hamper the treatment of certain concomitant
organisms, such as penicillin susceptible S. pneumoniae and
H. influenzae in cases of co-infection[1,5].
This study demonstrates that frequency of β-lactamase
production among M. catarrhalis is entirely consistent with

what reported globally[7-9]. Previous study from Pakistan
reported 68.7% β-lactamase production. However, in that
study they used less sensitive acidometric test for enzyme
detection[13]. Increasing frequency of enzyme production was
reported from the neighbouring country India. Larson et al.
reported enzyme production in 68% isolates in 1999 and Anita
et al. demonstrated 86% of isolates with enzyme activity in
2011[16-17].
In this study, high ampicillin MIC correlates well with high
β-lactamase production. Previously published work from
Pakistan reported 93.5% susceptibility to this drug. However,
that study had major limitation that authors did not test the
β-lactamase production in their isolates by the standard
method[12].
Another important and promising finding of our study
is that, resistance to other commonly used oral antibiotics
in CARTI such as tetracycline and erythromycin remained
low. Our finding regarding the tetracycline resistance is
comparable to those obtained from most Asia pacific regions
(3.2%) except Taiwan where it is around 19%[9,18]. Similarly
macrolide resistance is comparable to China 5.8%, however
it is much lower than that reported previously from Pakistan
(25%)[7,12].
Although ciprofloxacin is an accessible over the counter
drug in Pakistan and easily available with or without a
prescription, fortunately none of the isolate was found to be
ciprofloxacin resistant. This finding is consistent with other
reports published globally[7-9]. Though Tabussum et al. from
Karachi reported 7% and a study from India reported 20%
ciprofloxacin resistance[12,19].
G lobally, recovery of majority of the isolates from
respiratory samples from male patients was also observed in
this study[20]. We also found that M. catarrhalis infections
are more frequent among older age group. Similar finding
was reported from India and Nepal[20,21]. The predilection of
CARTI in the older age group has been studied and several
reasons have been proposed including age related changes
in systemic immunity, respiratory tract mucosal changes due
to smoking and several other co-morbidities[1,2,22].
Majority of isolates were recovered in winter season, which
is similar to finding of others[20-22]. A viral co-infection
has been anticipated as the mechanism for the seasonal
variation, it causes weakening of local immunity thereby
promoting infection by these pathogens[22].
This study is limited by its inability to perform molecular
detection of BRO 1 and 2 for identification of β-lactamase
enzymes. But it may be anticipated that majority were BRO 1
β-lactamase enzyme as they had high MICs for ampicillin[23].
I n summary, result of this study supports the
recommendation of BSAC in 2011 that clinical laboratories are
no more required to check the susceptibility of ampicillin
against M. catarrhalis and should report them resistant[24].
T herefore appropriate alternative antibiotic should be
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selected empirically in regard of treating CARTI. Finally we
emphasize the judicious use of antibiotics in this region and
continued surveillance to detect emerging resistance.
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